Korro Bio Doses First Participants in KRRO-121 Phase 1/2 Trial
The company announced dosing of healthy volunteers in its ANCHOR trial for KRRO-121, a potential treatment for urea cycle disorders, with patient dosing expected to begin in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed